LUMO Stock Overview
A clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Lumos Pharma, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.27 |
52 Week High | US$4.55 |
52 Week Low | US$2.01 |
Beta | 0.35 |
1 Month Change | -23.31% |
3 Month Change | -24.58% |
1 Year Change | -38.98% |
3 Year Change | -79.10% |
5 Year Change | n/a |
Change since IPO | -74.09% |
Recent News & Updates
Recent updates
We're A Little Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate
May 23We're Keeping An Eye On Lumos Pharma's (NASDAQ:LUMO) Cash Burn Rate
Aug 25Is Lumos Pharma (NASDAQ:LUMO) In A Good Position To Deliver On Growth Plans?
Mar 13Lumos Pharma announces new buyback program
Aug 16Here's Why We're Not Too Worried About Lumos Pharma's (NASDAQ:LUMO) Cash Burn Situation
Mar 22Companies Like Lumos Pharma (NASDAQ:LUMO) Are In A Position To Invest In Growth
Nov 04What Kind Of Investors Own Most Of Lumos Pharma, Inc. (NASDAQ:LUMO)?
Dec 09Lumos Pharma (LUMO) Investor Presentation - Slideshow
Nov 17Lumos Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 11Shareholder Returns
LUMO | US Biotechs | US Market | |
---|---|---|---|
7D | -1.7% | 2.4% | -0.6% |
1Y | -39.0% | 6.7% | 21.7% |
Return vs Industry: LUMO underperformed the US Biotechs industry which returned 6.3% over the past year.
Return vs Market: LUMO underperformed the US Market which returned 22.4% over the past year.
Price Volatility
LUMO volatility | |
---|---|
LUMO Average Weekly Movement | 9.5% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.6% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: LUMO's share price has been volatile over the past 3 months.
Volatility Over Time: LUMO's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 33 | Rick Hawkins | lumos-pharma.com |
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease.
Lumos Pharma, Inc. Fundamentals Summary
LUMO fundamental statistics | |
---|---|
Market cap | US$18.67m |
Earnings (TTM) | -US$37.13m |
Revenue (TTM) | US$1.53m |
12.1x
P/S Ratio-0.5x
P/E RatioIs LUMO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LUMO income statement (TTM) | |
---|---|
Revenue | US$1.53m |
Cost of Revenue | US$0 |
Gross Profit | US$1.53m |
Other Expenses | US$38.65m |
Earnings | -US$37.13m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -4.57 |
Gross Margin | 100.00% |
Net Profit Margin | -2,434.69% |
Debt/Equity Ratio | 0% |
How did LUMO perform over the long term?
See historical performance and comparison